I think the B-OM additional information mentioned for the presentation this Thursday could be huge, although I don't know exactly what to expect. To me, the B-OM indication is one that a BP focused on oncology would be very interested in. The current lack of a SOC that is viable and the existing safety profile for B and the fact that the mouthwash is easily administered could make this a very valuable indication. I hope that the results they present are further support of the numbers we have already seen.